Patent ID: 11905327
Assignee: NANJING LEGEND BIOTECH CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  Y | IPC A  C

Claim 13:
14. The anti-TIGIT construct of claim 10, wherein the full-length antibody specifically recognizes PD-L1, and wherein the full-length antibody comprises:
(a) an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 349, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 350, an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 351, an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 352, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 353, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 354;
(b) a VH comprising the amino acid sequence of SEQ ID NO: 339, and a VL comprising the amino acid sequence of SEQ ID NO: 340;
(c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 323 or 327, and a light chain comprising the amino acid sequence of SEQ ID NO: 328;
(d) a heavy chain comprising the amino acid sequence of SEQ ID NO: 329, and a light chain comprising the amino acid sequence of SEQ ID NO: 330;
(e) HC-CDRs of a VH comprising the amino acid sequence of SEQ ID NO: 379, and LC-CDRs of a VL comprising the amino acid sequence of SEQ ID NO: 380;
(f) HC-CDRs of a VH comprising the amino acid sequence of SEQ ID NO: 383, and LC-CDRs of a VL comprising the amino acid sequence of SEQ ID NO: 384;
(g) HC-CDRs of a VH comprising the amino acid sequence of SEQ ID NO: 381, and LC-CDRs of a VL comprising the amino acid sequence of SEQ ID NO: 382;
(h) a heavy chain comprising the amino acid sequence of SEQ ID NO: 331, and a light chain comprising the amino acid sequence of SEQ ID NO: 332; or
(i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 333, and a light chain comprising the amino acid sequence of SEQ ID NO: 334.